EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3

Molecular and Cellular Biology

Volumn 24, Issue 16, 2004, Pages 7275-7283

  Prieur, Alexandre ^a   Tirode, Franck ^a   Cohen, Pinchas ^b   Delattre, Olivier ^a  

^a INSTITUT CURIE   (France)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN FLI1; RNA BINDING PROTEIN EWS; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DNA FINGERPRINTING; EWING SARCOMA; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GENE FUSION; GENE INACTIVATION; GENE SEQUENCE; GENE SILENCING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REPRESSOR GENE; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UNINDEXED SEQUENCE;

APOPTOSIS; ARTIFICIAL GENE FUSION; BASE SEQUENCE; CELL LINE, TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; RNA INTERFERENCE; SARCOMA, EWING'S; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 3543026281     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.16.7275-7283.2004     Document Type: Article

References (36)

1. Arvand, A., and C. T. Denny. 2001. Biology of EWS/ETS fusions in Ewing's family tumors. Oncogene 20:5747-5754.
2. Bailly, R. A., R. Bosselut, J. Zucman, F. Cormier, O. Delattre, M. Roussel, G. Thomas, and J. Ghysdael. 1994. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11; 22) translocation in Ewing sarcoma. Mol. Cell. Biol. 14:3230-3241.
3. Baserga, R. 1995. The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res. 55:249-252.
4. II68, a novel RNA/ssDNA-binding protein with homology to the prooncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J. 15:5022-5031.
5. Cohen, P., D. R. Clemmons, and R. G. Rosenfeld. 2000. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm. IGF Res. 10:297-305.
6. Cohen, P., G. Lamson, T. Okajima, and R. G. Rosenfeld. 1993. Transfection of the human insulin-like growth factor binding protein-3 gene into Balb/c fibroblasts inhibits cellular growth. Mol. Endocrinol. 7:380-386.
7. Cubbage, M. L., A. Suwanichkul, and D. R. Powell. 1990. Insulin-like growth factor binding protein-3. Organization of the human chromosomal gene and demonstration of promoter activity. J. Biol. Chem. 265:12642-12649.
8. Delattre, O., J. Zucman, B. Plougastel, C. Desmaze, T. Melot, M. Peter, H. Kovar, I. Joubert, P. de Jong, G. Rouleau, et al. 1992. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 359:162-165.
9. Dohjima, T., N. Sook Lee, H. Li, T. Ohno, and J. J. Rossi. 2003. Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol. Ther. 7:811-816.
10. Jaishankar, S., J. Zhang, M. F. Roussel, and S. J. Baker. 1999. Transforming activity of EWS/FLI is not strictly dependent upon DNA-binding activity. Oncogene 18:5592-5597.
11. Kagan, H. M., and W. Li. 2003. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J. Cell Biochem. 88:660-672.
12. Kovar, H., D. N. Aryee, G. Jug, C. Henockl, M. Schemper, O. Delattre, G. Thomas, and H. Gadner. 1996. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ. 7:429-437.
13. Lambert, G., J. R. Bertrand, E. Fattal, F. Subra, H. Pinto-Alphandary, C. Malvy, C. Auclair, and P. Couvreur. 2000. EWS fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem. Biophys. Res. Commun. 279:401-406.
14. Lee, K. W., and P. Cohen. 2002. Nuclear effects: unexpected intracellular actions of insulin-like growth factor binding protein-3. J. Endocrinol. 175:33-40.
15. Lee, K. W., B. Liu, L. Ma, H. Li, P. Bang, H. P. Koeffler, and P. Cohen. 2004. Cellular internalization of insulin-like growth factor binding protein-3 (IG-FBP-3): distinct endocytic pathways facilitate reuptake and nuclear localization. J. Biol. Chem. 279:469-476.
16. Melot, T., N. Gruel, A. Doubeikovski, N. Sevenet, J. L. Teillaud, and O. Delattre. 1997. Production and characterization of mouse monoclonal antibodies to wild-type and oncogenic FLI-1 proteins. Hybridoma 16:457-464.
17. Ohno, T., V. N. Rao, and E. S. Reddy. 1993. EWS/Fli-1 chimeric protein is a transcriptional activator. Cancer Res. 53:5859-5863.
18. Ouchida, M., T. Ohno, Y. Fujimura, V. N. Rao, and E. S. Reddy. 1995. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 11:1049-1054.
19. Peruzzi, F., M. Prisco, M. Dews, P. Salomoni, E. Grassilli, G. Romano, B. Calabretta, and R. Baserga. 1999. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol. Cell. Biol. 19:7203-7215.
20. Rajah, R., B. Valentinis, and P. Cohen. 1997. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-β1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 272:12181-12188.
21. Schedlich, L. J., T. F. Young, S. M. Firth, and R. C. Baxter. 1998. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J. Biol. Chem. 273:18347-18352.
22. Scotlandi, K., S. Avnet, S. Benini, M. C. Manara, M. Serra, V. Cerisano, S. Perdichizzi, P. L. Lollini, C. De Giovanni, L. Landuzzi, and P. Picci. 2002. Expression of an IGF-1 receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int. J. Cancer 101:11-16.
23. Scotlandi, K., S. Benini, P. Nanni, P. L. Lollini, G. Nicoletti, L. Landuzzi, M. Serra, M. C. Manara, P. Picci, and N. Baldini. 1998. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 58:4127-4131.
24. Scotlandi, K., C. Maini, M. C. Manara, S. Benini, M. Serra, V. Cerisano, R. Strammiello, N. Baldini, P. L. Lollini, P. Nanni, G. Nicoletti, and P. Picci. 2002. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther. 9:296-307.
25. Sekyi-Otu, A., R. S. Bell, C. Ohashi, M. Pollak, and I. L. Andrulis. 1995. Insulin-like growth factor 1 (IGF-1) receptors, IGF-1, and IGF-2 are expressed in primary human sarcomas. Cancer Res. 55:129-134.
26. Sell, C., M. Rubini, R. Rubin, J. P. Liu, A. Efstratiadis, and R. Baserga. 1993. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. Natl. Acad. Sci. USA 90:11217-11221.
27. Sementchenko, V. I., and D. K. Watson. 2000. Ets target genes: past, present and future. Oncogene 19:6533-6548.
28. Sidenius, N., and F. Blasi. 2003. The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev. 22:205-222.
29. Singh, B. K., D. A. Charkowicz, and D. D. Mascarenhas. 2004. Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. J. Biol. Chem. 279:477-487.
30. Surmacz, E. 2003. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor. Oncogene 22:6589-6597.
31. Tanaka, K., T. Iwakuma, K. Harimaya, H. Sato, and Y. Iwamoto. 1997. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J. Clin. Investig. 99:239-247.
32. Torchia, E. C., S. Jaishankar, and S. J. Baker. 2003. Ewing tumor fusion proteins block the differentiation of pluripotent marrow stromal cells. Cancer Res. 63:3464-3468.
33. Toretsky, J. A., T. Kalebic, V. Blakesley, D. LeRoith, and L. J. Helman. 1997. The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J. Biol. Chem. 272:30822-30827.
34. Valentinis, B., and R. Baserga. 2001. IGF-I receptor signalling in transformation and differentiation. Mol. Pathol. 54:133-137.
35. Werner, H., M. Shalita-Chesner, S. Abramovitch, G. Idelman, L. Shaharabani-Gargir, and T. Glaser. 2000. Regulation of the insulin-like growth factor-I receptor gene by oncogenes and antioncogenes: implications in human cancer. Mol. Genet. Metab. 71:315-320.
36. Yamanaka, Y., J. L. Fowlkes, E. M. Wilson, R. G. Rosenfeld, and Y. Oh. 1999. Characterization of insulin-like growth factor binding protein-3 (IG-FBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 140:1319-1328.